MORRISVILLE – Metabolon, a privately held and growing entrepreneurial company focusing on precision medicine, has wrapped up a new round of fundraising with $72 million in debt and equity.

The company announced the funding news Wednesday.

A week ago, Metabolon disclosed in an SEC filing the raising of $21.8 million from 11 investors with a targeted amount of nearly $50 million.

“This incremental funding will help accelerate our growth and expand our client base, in addition to helping further our R&D programs in machine learning to enable novel biomarker discovery and expand our precision medicine platform,” a company spokesperson said at that time.

Precision medicine firm Metabolon looks to raise $48M – and investors are on board

Investors in the $72 million round include Perceptive Advisors. EW Healthcare Partners and other previous investors.

“We are thrilled by this strong show of support from Perceptive Advisors and our current investors,” said Rohan Hastie, Metabolon’s CEO. “I am also extremely excited that some of the company’s earliest investors participated in this round of investment as well. The incremental funding will help accelerate our growth and expand our client base, in addition to helping further our R&D programs in machine learning to enable novel biomarker discovery and expand our precision medicine platform.”

Founded in 2000, the startup specializes in a technology called metabolomics, which is the large-scale study of small molecules, commonly known as metabolites, within cells, biofluids, tissues or organisms.

Metabolon’s proprietary Precision Metabolomics technology provides researchers with the ability to profile a subject’s or patient’s metabolome for applications in precision medicine and to advance understanding of the metabolic basis of disease, disease progression and treatment mechanisms.